Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | CA12 | O43570 | 3/20 | 0.59 |
| ▸ | CA1 | P00915 | 3/20 | 0.59 |
| ▸ | CA2 | P00918 | 3/20 | 0.59 |
| ▸ | CA7 | P43166 | 3/20 | 0.59 |
| ▸ | CA9 | Q16790 | 3/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.59 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.59 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | EGFR | P00533 | 3/20 | 0.52 |
| ▸ | MYC | P01106 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5460237 | 0.82 | TDP1 (0.48) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL7331267 | 0.81 | SMN1; SMN2 (0.70) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL15903856 | 0.81 | KMT2A (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2127575 | 0.78 | SMN1; SMN2 (1.00) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL613429 | 0.78 | SMN1; SMN2 (0.76) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL135979 | 0.77 | CA12 (0.69) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL5461908 | 0.77 | SMN1; SMN2 (0.64) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL15763208 | 0.77 | SMN1; SMN2 (0.64) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL31737842 | 0.76 | EGFR (0.59) | SMN1; SMN2CA12CA1CA2CA7 | |
| SCHEMBL15754433 | 0.75 | SMN1; SMN2 (0.62) | SMN1; SMN2CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1666469-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | SMN1; SMN2 2862/4885CA12 2735/4885CA1 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.